Page last updated: 2024-10-23

aspirin and Day Blindness

aspirin has been researched along with Day Blindness in 36 studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Research Excerpts

ExcerptRelevanceReference
"Follow-up study of the 214 surviving patients enrolled originally at the Johns Hopkins Clinical Center for the Early Treatment Diabetic Retinopathy Study (ETDRS), which was a clinical trial designed to evaluate the role of laser photocoagulation and aspirin treatment in patients with diabetic retinopathy."5.10The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. ( Agrón, E; Chew, EY; Csaky, KG; Ferris, FL; Murphy, RP; Reed, GF; Schachat, AP; Thompson, DJ, 2003)
"Aspirin has a well established role in the prevention of arterial thrombosis."4.79Aspirin in essential thrombocythemia: status quo and quo vadis. ( Bangerter, M; Griesshammer, M; Michiels, JJ; van Vliet, HH, 1997)
"In the final regression model, VFD was associated with maternal consumption of aspirin during the current pregnancy, recurring/persistent acidemia during the first 3 postnatal days, cerebral ventriculomegaly seen on neonatal ultrasound, prethreshold retinopathy of prematurity (ROP), and supplemental oxygen and ventilator dependence at 36 weeks post-menstrual age."3.81Antecedents and correlates of visual field deficits in children born extremely preterm. ( Allred, E; Dammann, O; Holm, M; Leviton, A; Msall, ME; Skranes, J, 2015)
"Susac's syndrome is an extremely rare clinical manifestation characterized by the triad of fluctuating sensorineural hearing loss, sudden visual loss and encephalopathy."2.41[Susac syndrome as a cause of sensorineural hearing loss]. ( Albaladejo Devis, I; Cubillana Herrero, JD; Jiménez Cervantes-Nicolás, JA; Minguez Merlos, N; Rodríguez González-Herrero, B; Soler Valcárcel, A, 2002)
"In comparison with transient ischemic attacks in patients with vascular risk factors, the usual neurologic presentation of ET consists of brief attacks of sudden cerebral or visual dysfunction, which can be either well localized or diffuse and entirely nonspecific."2.40Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin. ( Koudstaal, A; Koudstaal, PJ, 1997)
"Associations between retinal vein thrombosis and other systemic disorders have been well documented, but a comprehensive literature search failed to reveal any report of essential thrombocythemia as a cause of central retinal vein thrombosis."1.33Retinal vein thrombosis as the presenting symptom of essential thrombocythemia. ( Aithal, S; Huang, YW; Marshak, H; Novetsky, A; Saffra, N; Tache, JE, 2005)
"To report a case of Dengue fever resulting in permanent visual loss in both eyes due to retinal capillary occlusion."1.32Ocular manifestations in Dengue fever. ( Campos, WR; de Moraes Figueiredo, LT; Oréfice, F; Siqueira, RC; Vitral, NP, 2004)
"Treatment with aspirin and prednisone in one patient."1.29Anterior ischemic optic neuropathy secondary to interferon alfa. ( Purvin, VA, 1995)
"Recurrent transient ischemic attack or amaurosis fugax occurred more frequently (P less than 0."1.27Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks. ( Eriksson, SE, 1985)
"Hallucinations were either unformed (for example, bright lights, straight lines) or highly formed (for example, faces), in which case they were invariably recognized by the patient as inappropriate."1.25Cerebral disorders of vision in systemic lupus erythematosus. ( Brandt, KD; Cohen, AS; Lessell, S, 1975)

Research

Studies (36)

TimeframeStudies, this research(%)All Research%
pre-19909 (25.00)18.7374
1990's8 (22.22)18.2507
2000's11 (30.56)29.6817
2010's6 (16.67)24.3611
2020's2 (5.56)2.80

Authors

AuthorsStudies
Hočevar, A1
Ješe, R1
Tomšič, M1
Rotar, Ž1
Stanescu, N1
Wood, K1
Greenberg, T1
Maklakovski, M1
Rubinov, A1
Dagan, A1
Nesher, G1
Poltorak, V1
Hindi, I1
Nesher, R1
Dror, Y1
Orbach, H1
Breuer, GS1
Dari, ML1
Nguyen, C1
Wolfensberger, TJ1
Pournaras, JA1
Holm, M1
Msall, ME1
Skranes, J1
Dammann, O1
Allred, E1
Leviton, A1
Hughes, WM1
Villalon-Gomez, JM1
Futch, D1
Schneider, MJ1
Murphy, D1
Grayev, A1
Beato, J1
Fígueira, L1
Penas, S1
Santos-Silva, R1
Falcão, M1
Carneiro, Â1
Reis, FF1
Stoffelns, BM1
Borg, FA1
Salter, VL1
Dasgupta, B1
Berger, CT1
Wolbers, M1
Meyer, P1
Daikeler, T1
Hess, C1
Dörr, J1
Radbruch, H1
Bock, M1
Wuerfel, J1
Brüggemann, A1
Wandinger, KP1
Zeise, D1
Pfueller, CF1
Zipp, F1
Paul, F1
Cubillana Herrero, JD1
Soler Valcárcel, A1
Albaladejo Devis, I1
Rodríguez González-Herrero, B1
Minguez Merlos, N1
Jiménez Cervantes-Nicolás, JA1
Chew, EY2
Ferris, FL2
Csaky, KG1
Murphy, RP1
Agrón, E1
Thompson, DJ1
Reed, GF1
Schachat, AP1
Siqueira, RC1
Vitral, NP1
Campos, WR1
Oréfice, F1
de Moraes Figueiredo, LT1
Tache, JE1
Saffra, N1
Marshak, H1
Aithal, S1
Novetsky, A1
Huang, YW1
Löw, U1
Kohlhof, JK1
Ruprecht, KW1
Purvin, VA1
Wildemann, B1
Schülin, C1
Storch-Hagenlocher, B1
Hacke, W1
Dithmar, S1
Kirchhof, K1
Jansen, O1
Breitbart, A1
Michiels, JJ2
van Genderen, PJ1
Jansen, PH1
Koudstaal, PJ2
Ferris, F1
Koudstaal, A1
Griesshammer, M1
Bangerter, M1
van Vliet, HH1
Davis, MD1
Fisher, MR1
Gangnon, RE1
Barton, F1
Aiello, LM1
Knatterud, GL1
Leo-Kottler, B1
Klein, R1
Berg, PA1
Zrenner, E1
Nakai, K1
Tajima, K1
Kishimoto, Y1
Katsura, K1
Kawamura, M1
Yamamoto, Y1
Hanada, M1
Zen, K1
Amakawa, R1
Fujimoto, M1
Fukuhara, S1
McDonald, HR1
Marshall, J1
Brandt, KD1
Lessell, S1
Cohen, AS1
Levy, NS1
Hanscom, T1
Wolf, PA1
Eriksson, SE1
Lamphier, T1
Rodriguez, A1
Richards, D1
Rosner, S1
Watillon, M1
Robe-Vanwijck, A1
Holmes, EL1

Clinical Trials (7)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (GCA).[NCT00974883]880 participants (Actual)Observational2010-06-30Completed
Investigation of Relevant Biomarkers in Patients With Susac Syndrome[NCT01273792]30 participants (Anticipated)Observational2010-05-31Recruiting
Aqueous Biomarker Levels in Diabetic Retinopathy and Diabetic Macular Edema[NCT05333055]150 participants (Anticipated)Observational2022-04-11Not yet recruiting
[NCT00000151]Phase 30 participants Interventional1979-12-31Completed
Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial[NCT04708145]Phase 4150 participants (Anticipated)Interventional2021-06-01Active, not recruiting
Intravitreal Aflibercept for Retinal Non-Perfusion in Proliferative Diabetic Retinopathy[NCT02863354]Phase 243 participants (Actual)Interventional2016-08-31Completed
Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement[NCT03531294]Phase 240 participants (Actual)Interventional2018-05-23Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Area of Retinal Capillary Non-perfusion Outside of the Macula

Change in area of retinal capillary non-perfusion outside of the macula from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks

,
Interventionmm^2 (Mean)
Week 52Week 100
Q12WKS240.472387.204
Q4WKS182.467342.651

Change in Area of Retinal Capillary Non-perfusion Within the Macula

Change in area of retinal capillary non-perfusion within the macula compared to baseline, as assessed by ultrawide-field fluorescein angiogram from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks

,
Interventionmm^2 (Mean)
Week 52Week 100
Q12WKS0.2170.940
Q4WKS0.0482.627

Change in Area of Total Retinal Capillary Non-perfusion, as Assessed by the Central Reading Center

Change in area of total retinal capillary non-perfusion, as assessed by the central reading center, at week 52 and week 100 compared to baseline. (NCT02863354)
Timeframe: 52 weeks and 100 weeks

,
Interventionmm^2 (Mean)
Week 52Week 100
Q12WKS66.752245.694
Q4WKS-11.994141.317

Change in Early Treatment of Diabetic Retinopathy Severity Best Corrected Visual Acuity

Mean change in Early Treatment of Diabetic Retinopathy Study Best Corrected Visual Acuity (ETDRS-BCVA) from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 weeks and 100 weeks

,
InterventionETDRS letters (Mean)
Week 52Week 100
Q12WKS4.538.88
Q4WKS4.264.06

Changes in Visual Function Outcomes (Self Reported Visual Function)

Changes in self reported visual function utilizing the National Eye Institute Visual Function Questionnaire-25 (NEI VFQ-25) from baseline to week 52 and week 100. The NEI VFQ is a validated measure of patient-reported visual function measured on a scale from 0 (worst function) to 100 (best function). (NCT02863354)
Timeframe: 52 weeks and 100 weeks

,
Interventionunits on a scale (Mean)
Week 52Week 100
Q12WKS2.238.82
Q4WKS6.278.91

Mean Change in Central Subfield Thickness

Mean change in central subfield thickness (CST) from baseline to week 52 and week 100 (NCT02863354)
Timeframe: 52 weeks and 100 weeks

,
Interventionmicrometers (Mean)
Week 52Week 100
Q12WKS-20.813-23.313
Q4WKS-32.947-35.059

Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0

• Assess the safety and tolerability of IAI for the treatment of proliferative diabetic retinopathy by evaluating the incidence and severity of ocular and systemic adverse events through week 52 and week 100. (NCT02863354)
Timeframe: 52 and 100 weeks

,
InterventionParticipants (Count of Participants)
Week 52Week 100
Q12WKS00
Q4WKS00

Percentage of Subjects Treated With Pan-retinal Photocoagulation or Vitrectomy

Percentage of subjects treated with PRP or vitrectomy for progression of PDR from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

,
InterventionParticipants (Count of Participants)
Week 52Week 100
Q12WKS00
Q4WKS00

Percentage of Subjects Who Develop Center-involving Diabetic Macular Edema

Percentage of subjects, at week 52 and week 100, who develop center-involving diabetic macular edema who did not have center-involving diabetic macular edema at baseline (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

,
InterventionParticipants (Count of Participants)
Week 52Week 100
Q12WKS00
Q4WKS00

Percentage of Subjects Who Develop Vitreous Hemorrhage

Percentage of subjects who develop vitreous hemorrhage from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

,
InterventionParticipants (Count of Participants)
Week 52Week 100
Q12WKS11
Q4WKS24

Percentage of Subjects With Increased Neovascularization

Percentage of subjects with increased neovascularization from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

,
InterventionParticipants (Count of Participants)
Week 52Week 100
Q12WKS00
Q4WKS10

Percentage of Subjects With Neovascularization Regression

Percentage of subjects with neovascularization regression (reduced area of neovascularization) as measured by the central image reading center from baseline to week 52 and week 100. (NCT02863354)
Timeframe: 52 Weeks and 100 Weeks

,
InterventionParticipants (Count of Participants)
Week 52Week 100
Q12WKS1815
Q4WKS1717

Reviews

5 reviews available for aspirin and Day Blindness

ArticleYear
Neuro-ophthalmic complications in giant cell arteritis.
    Current allergy and asthma reports, 2008, Volume: 8, Issue:4

    Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Aspirin; Cytokines; Giant Cell Arteritis; Humans;

2008
[Susac syndrome as a cause of sensorineural hearing loss].
    Acta otorrinolaringologica espanola, 2002, Volume: 53, Issue:5

    Topics: Adult; Anti-Inflammatory Agents; Aspirin; Cerebral Infarction; Cochlea; Combined Modality Therapy; D

2002
Atypical transient ischemic attacks in thrombocythemia of various myeloproliferative disorders.
    Leukemia & lymphoma, 1996, Volume: 22 Suppl 1

    Topics: Adult; Aged; Aspirin; Capillaries; Cerebral Arteries; Diagnosis, Differential; Erythromelalgia; Fema

1996
Neurologic and visual symptoms in essential thrombocythemia: efficacy of low-dose aspirin.
    Seminars in thrombosis and hemostasis, 1997, Volume: 23, Issue:4

    Topics: Anticoagulants; Aspirin; Brain Ischemia; Diagnosis, Differential; Erythromelalgia; Headache; Humans;

1997
Aspirin in essential thrombocythemia: status quo and quo vadis.
    Seminars in thrombosis and hemostasis, 1997, Volume: 23, Issue:4

    Topics: Abortion, Habitual; Aspirin; Cerebrovascular Disorders; Cohort Studies; Contraindications; Erythrome

1997

Trials

5 trials available for aspirin and Day Blindness

ArticleYear
The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study.
    Ophthalmology, 2003, Volume: 110, Issue:9

    Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cataract; Diabetic Retinopathy; Femal

2003
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Early photocoagulation in patients with either type I or type II diabetes.
    Transactions of the American Ophthalmological Society, 1996, Volume: 94

    Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitu

1996
Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18.
    Investigative ophthalmology & visual science, 1998, Volume: 39, Issue:2

    Topics: Adolescent; Adult; Aged; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Neu

1998
Double-blind study of the analgesic effect of ethoheptazine-aspirin.
    Current therapeutic research, clinical and experimental, 1974, Volume: 16, Issue:7

    Topics: Adolescent; Adult; Aged; Analysis of Variance; Aspirin; Azepines; Clinical Trials as Topic; Depressi

1974
Experimental observations on flufenamic, mefenamic, and meclofenamic acids. IV. Toleration by normal human subjects.
    Annals of physical medicine, 1966, Volume: Suppl

    Topics: Adult; Anti-Inflammatory Agents; Aspirin; Biphenyl Compounds; Blood Coagulation; Blood Urea Nitrogen

1966

Other Studies

26 other studies available for aspirin and Day Blindness

ArticleYear
Risk factors for severe cranial ischaemic complications in giant cell arteritis.
    Rheumatology (Oxford, England), 2020, 10-01, Volume: 59, Issue:10

    Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Ischem

2020
Hemi-central Retinal Artery Occlusion Associated with Giant Cell Arteritis.
    The Israel Medical Association journal : IMAJ, 2021, Volume: 23, Issue:7

    Topics: Anti-Inflammatory Agents; Aspirin; Biomarkers; Biopsy; Female; Fluorescein Angiography; Fundus Oculi

2021
Survival of patient with giant cell arteritis: Impact of vision loss and treatment with aspirin.
    Autoimmunity reviews, 2019, Volume: 18, Issue:8

    Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Giant Cell Arteri

2019
Systematic treatment of central retinal vein occlusion.
    Klinische Monatsblatter fur Augenheilkunde, 2013, Volume: 230, Issue:4

    Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Combined Modality Therapy; Folic Acid; Humans; Lig

2013
Antecedents and correlates of visual field deficits in children born extremely preterm.
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2015, Volume: 19, Issue:1

    Topics: Acidosis; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebral Ventricles; Child Develo

2015
Bifrontal headache · blurred vision · vomiting · Dx?
    The Journal of family practice, 2015, Volume: 64, Issue:6

    Topics: Aspirin; Clopidogrel; Diagnosis, Differential; Drug Therapy, Combination; Female; Headache; Humans;

2015
Vertebral artery dissection in evolution found during chiropractic examination.
    BMJ case reports, 2015, Nov-12, Volume: 2015

    Topics: Adult; Aspirin; Female; Humans; Magnetic Resonance Angiography; Neck Pain; Platelet Aggregation Inhi

2015
Presumed bilateral cilioretinal artery occlusion related to relapsing white dot syndrome.
    European journal of ophthalmology, 2016, Aug-04, Volume: 26, Issue:5

    Topics: Arterial Occlusive Diseases; Aspirin; Ciliary Arteries; Coloring Agents; Drug Therapy, Combination;

2016
[Central Retinal Vein Occlusion accompanied by positive testing of serum antineutrophil cytoplasmic antibodies (c-ANCA)].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2008, Volume: 105, Issue:12

    Topics: Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Aspirin; Combined Modality Therapy

2008
High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.
    Rheumatology (Oxford, England), 2009, Volume: 48, Issue:3

    Topics: Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cell Size; Female; Giant Cell Art

2009
Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome.
    Nature reviews. Neurology, 2009, Volume: 5, Issue:12

    Topics: Aspirin; Auditory Perceptual Disorders; Brain; Cerebral Angiography; Diagnosis, Differential; Diseas

2009
Ocular manifestations in Dengue fever.
    Ocular immunology and inflammation, 2004, Volume: 12, Issue:4

    Topics: Adult; Antibodies, Viral; Aspirin; Combined Modality Therapy; Dengue; Dengue Virus; Enzyme-Linked Im

2004
Retinal vein thrombosis as the presenting symptom of essential thrombocythemia.
    The American journal of the medical sciences, 2005, Volume: 329, Issue:3

    Topics: Adult; Aspirin; Diagnosis, Differential; Female; Fibrinolytic Agents; Humans; Retinal Vein Occlusion

2005
[Does acetylsalicylic acid have a negative influence on photodynamic therapy?].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2006, Volume: 103, Issue:3

    Topics: Aged; Aspirin; Choroidal Neovascularization; Drug Combinations; Female; Humans; Macular Degeneration

2006
Anterior ischemic optic neuropathy secondary to interferon alfa.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1995, Volume: 113, Issue:8

    Topics: Acute Disease; Adult; Aspirin; Carcinoma, Renal Cell; Fundus Oculi; Humans; Interferon-alpha; Ischem

1995
Susac's syndrome: improvement with combined antiplatelet and calcium antagonist therapy.
    Stroke, 1996, Volume: 27, Issue:1

    Topics: Adult; Aspirin; Calcium Channel Blockers; Cerebrovascular Disorders; Drug Combinations; Female; Hear

1996
Ocular symptoms in association with antiphospholipid antibodies.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 1998, Volume: 236, Issue:9

    Topics: Adolescent; Adult; Aged; Antibodies, Antiphospholipid; Antiphospholipid Syndrome; Aspirin; Drug Ther

1998
[Bone marrow transplantation-associated thrombotic microangiopathy manifested by visual disturbance].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2000, Volume: 41, Issue:1

    Topics: Adult; Aspirin; Bone Marrow Transplantation; Dipyridamole; Female; Humans; Leukemia, Myeloid, Acute;

2000
Diagnostic and therapeutic challenges.
    Retina (Philadelphia, Pa.), 2000, Volume: 20, Issue:2

    Topics: Adult; Aspirin; Female; Fluorescein Angiography; Humans; Plasmapheresis; Prednisone; Purpura, Thromb

2000
Microembolisation as a cause of clinical disorders.
    Acta clinica Belgica, 1977, Volume: 32, Issue:1

    Topics: Aspirin; Humans; Intracranial Embolism and Thrombosis; Ischemic Attack, Transient; Vision Disorders;

1977
Cerebral disorders of vision in systemic lupus erythematosus.
    Annals of internal medicine, 1975, Volume: 83, Issue:2

    Topics: Adrenal Cortex Hormones; Adult; Aspirin; Brain Diseases; Cerebrospinal Fluid; Electroencephalography

1975
Letter: Ibuprofen and visual function.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1976, Volume: 94, Issue:5

    Topics: Aged; Arthritis, Rheumatoid; Aspirin; Eye; Female; Humans; Ibuprofen; Osteoarthritis; Phenylpropiona

1976
Transient ischemic attacks. Locating the source.
    Hospital practice (Office ed.), 1985, May-30, Volume: 20, Issue:5A

    Topics: Aged; Aspirin; Blood Coagulation; Carotid Artery Diseases; Cerebrovascular Circulation; Diagnosis, D

1985
Enteric-coated acetylsalicylic acid plus dipyridamole compared with anticoagulants in the prevention of ischemic events in patients with transient ischemic attacks.
    Acta neurologica Scandinavica, 1985, Volume: 71, Issue:6

    Topics: Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Dipyridamole; Drug Therapy, Combination; F

1985
The diagnosis and treatment of cerebral concussion.
    International surgery, 1967, Volume: 47, Issue:4

    Topics: Ascorbic Acid; Aspirin; Brain Concussion; Cerebral Ventriculography; Cortisone; Diphenhydramine; Ele

1967
[Harmful effects of common drugs on the visual apparatus. Minor analgesics, antipyretics, nonsteroid anti-inflammatory and antirheumatic drugs].
    Bulletin de la Societe belge d'ophtalmologie, 1972, Volume: 160, Issue:1

    Topics: Analgesics; Anti-Inflammatory Agents; Antimalarials; Aspirin; Color Vision Defects; Corneal Opacity;

1972